ascendis transcon glp-1 program Pharma announced that the U.S. Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide, PTH,) injection as the First and Only treatment for adults with hyperparathyroidism. Palopegteriparatide is a prodrug Issue 42: GLP-1 RA Drug
Pay in 4 interest-free payments of $6.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5














:max_bytes(150000):strip_icc()/Health-GettyImages-2242656837-7ba7eeb1b08d43c681f154b32e6dc07c.jpg)











